Takeda Builds On Vaccines With Inviragen Acquisition
This article was originally published in The Pink Sheet Daily
Executive Summary
The Japanese pharma will pay $35 million to acquire the private vaccines maker, which has a dengue vaccine in Phase II development. Takeda has made vaccines a priority and has been actively building the business through acquisitions.
You may also be interested in...
Takeda Test Drives EMA’s Parallel Review Route For EU And Non-EU Markets
A new evaluation route that the European Medicines Agency launched last year came at the right time for Takeda’s dengue vaccine candidate.
New Therapeutic Areas Ignite Investor Interest Amid Pandemic Reset
Investor attention is turning increasingly to new products and new areas of growth like obesity, Alzheimer’s disease and RSV as big blockbusters face increasing competitive pressure.
Merck Files First IRA Suit, Signaling Industry Is Ready To Fight
Coming less than three months before the statutory deadline for CMS to publish the initial list of drugs, Merck’s lawsuit calls US Medicare drug price negotiations ‘extortion’ in a complaint that could be the first of more legal pushback to follow.